Psychiatry Update 2022

Access this Glossary of Psychiatric Medications for a listing of common antidepressants, typical and atypical antipsychotics, common benzodiazepines, anxiolytics, hypnotics, mood stabilizers and more.

This presentation on antipsychotic treatment of schizophrenia reviews the mechanism, efficacy, and safety of existing and emerging antipsychotics in the treatment selection for people with schizophrenia.

Christoph U. Correll, MD Robert O. Cotes, MD Released: May 11, 2022

This presentation on managing bipolar depression and mixed presentations reviews the dimensional continuum of mood disorder presentations from unipolar to bipolar disorder, evidence supporting the use and limitations of mood-stabilizing drugs and second-generation antipsychotics for the treatment of unipolar and bipolar depression, limitations of monoaminergic antidepressants in bipolar depression and major depression with mixed features, and evidence-based patient treatment plans based upon patient and disease state-specific characteristics.

Charles DeBattista, MD Roger McIntyre, MD, FRCPC Released: May 9, 2022

This presentation on managing major depression reviews the unmet needs in major depression as they relate to current treatment strategies, evidence supporting the use of atypical antipsychotics as augmentation therapy in major depression, and evidence-based patient treatment plans based on patient- and disease state–specific characteristics.

Manish Jha, MD Greg Mattingly, MD Released: May 11, 2022

This presentation on recent updates in ADHD: optimizing outcomes in a digital world reviews the impact of screen time and social media on processing speed and ADHD symptoms throughout the lifespan; the impact of unrecognized or untreated ADHD on mortality rates, school performance, job performance, and daily social function; and strategies and options to optimize ADHD care within your practice.

Greg Mattingly, MD Joel L. Young, MD Released: May 6, 2022

This presentation on the identification and management of tardive dyskinesia 2022 reviews the relative prevalence of TD in patients with schizophrenia, mood spectrum disorders, and anxiety disorders; and the effective use of VMAT2 inhibitors without discontinuing other essential psychiatric treatments such as antipsychotics and antidepressants.

Christoph U. Correll, MD Robert O. Cotes, MD Released: May 11, 2022